S

Sanjivani Paranteral Ltd
BSE:531569

Watchlist Manager
Sanjivani Paranteral Ltd
BSE:531569
Watchlist
Price: 235.15 INR -0.3% Market Closed
Market Cap: 2.9B INR
Section:
 

Relative Value

The Relative Value of one SANJIVIN stock under the Base Case scenario is hidden INR. Compared to the current market price of 235.15 INR, Sanjivani Paranteral Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SANJIVIN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

3.9
P/S
P/S
Price to Sales
3.9
vs History
33
vs Industry
26
Median 3Y
3.6
Median 5Y
1.9
Industry
2.6
More Details
34.4
P/E
P/E
Price to Earnings
34.4
vs History
31
vs Industry
9
Median 3Y
31.1
Median 5Y
14.6
Industry
21.4
More Details
22.5
P/OCF
P/OCF
Price to OCF
22.5
vs History
19
vs Industry
13
Median 3Y
-20.6
Median 5Y
0
Industry
16.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
7
Median 3Y
-26.4
Median 5Y
0
Industry
22.8
More Details
7.4
P/B
P/B
Price to Book Value
7.4
vs History
39
vs Industry
6
Median 3Y
7.6
Median 5Y
-0.7
Industry
2.2
More Details
4
EV/S
EV/S
Enterprise Value to Sales
4
vs History
33
vs Industry
25
Median 3Y
3.7
Median 5Y
2
Industry
2.9
More Details
9.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
9.4
vs History
26
vs Industry
19
Median 3Y
8.2
Median 5Y
3.9
Industry
5.5
More Details
26.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
26.8
vs History
31
vs Industry
10
Median 3Y
24.6
Median 5Y
14.1
Industry
13
More Details
28.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
28.5
vs History
33
vs Industry
12
Median 3Y
26.7
Median 5Y
14.1
Industry
16.5
More Details
23
EV/OCF
EV/OCF
Enterprise Value to OCF
23
vs History
19
vs Industry
13
Median 3Y
-19.8
Median 5Y
0
Industry
15.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
6
Median 3Y
-16.6
Median 5Y
0
Industry
18.7
More Details
4.7
EV/IC
EV/IC
Enterprise Value to IC
4.7
vs History
79
vs Industry
11
Median 3Y
8.1
Median 5Y
8
Industry
1.9
More Details

Multiples Across Competitors

SANJIVIN Competitors Multiples
Sanjivani Paranteral Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Sanjivani Paranteral Ltd
BSE:531569
2.8B INR 3.9 34.4 26.8 28.5
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.6 56.7 38 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
499.2B USD 5.4 19.9 16.3 21.1
CH
Roche Holding AG
SIX:ROG
267.7B CHF 4.3 28.4 12.1 14.1
UK
AstraZeneca PLC
LSE:AZN
220.3B GBP 5.1 31.6 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
276B USD 4.3 14.5 10.3 12.2
CH
Novartis AG
SIX:NOVN
218.3B CHF 4.9 19.1 12.1 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.6 10.9 12.6
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.9 7.6 10.3
P/E Multiple
Earnings Growth PEG
IN
S
Sanjivani Paranteral Ltd
BSE:531569
Average P/E: 26.1
34.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
56.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.6
37%
0.9
US
Merck & Co Inc
NYSE:MRK
14.5
15%
1
CH
Novartis AG
SIX:NOVN
19.1
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
15.6
3%
5.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.9
27%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
S
Sanjivani Paranteral Ltd
BSE:531569
Average EV/EBITDA: 402.5
26.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.3
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.1
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.3
6%
1.7
CH
Novartis AG
SIX:NOVN
12.1
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
10.9
1%
10.9
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
S
Sanjivani Paranteral Ltd
BSE:531569
Average EV/EBIT: 1 715.1
28.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.1
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.1
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.2
8%
1.5
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
12.6
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5

See Also

Summary
SANJIVIN intrinsic value, competitors valuation, and company profile.
DCF Valuation
SANJIVIN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SANJIVIN stock valuation using valuation multiples.
Wall Street Estimates
SANJIVIN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SANJIVIN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,900+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.